MA28104A1 - Sel antagonistes de ccr-2 - Google Patents

Sel antagonistes de ccr-2

Info

Publication number
MA28104A1
MA28104A1 MA28957A MA28957A MA28104A1 MA 28104 A1 MA28104 A1 MA 28104A1 MA 28957 A MA28957 A MA 28957A MA 28957 A MA28957 A MA 28957A MA 28104 A1 MA28104 A1 MA 28104A1
Authority
MA
Morocco
Prior art keywords
salt
ccr
antagonists
succinate salt
methoxytetrahydro
Prior art date
Application number
MA28957A
Other languages
English (en)
Inventor
Mark Jensen
Robert Larsen
Daniel Richard Sidler
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA28104A1 publication Critical patent/MA28104A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention fournit une synthèse efficace pour la préparation de ((1R,3S)-3-isopropyl-3-{[3-(trifluorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl] carbonyl} cyclopentyl) [(3S,4S)-3-méthoxytétrahydro-2H-pyran-4-yl] aminé et son sel succinate. La présente invention fournit en plus une synthèse efficace pour la préparation des intermédiaires (3R)-3-méthoxytétrahydro-4H-pyran-4-one; acide (1S,4S)-4-(2,5-diméthyl- 1H-pyrrol- 1-yl)-1-isopropylcyclopent-2-ene-1-carboxylique; et 3-(trifluorométhyl)-5,6,7,8-tétrahydro-1,6-naphtydirine; et pour la préparation du précurseur (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(trifluorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl] carbonyl} cyclopent-2-en-1-yl)-3-méthoxytétrahydro-2H-pyran-4-amine. L'invention concerne en outre les propriétés supérieures du sel succinate de ((1R,3S)-3-isopropyl-3-{[3-(trifiuorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl]carbonyl}cyclopentyl) [(3S,4S)-3-méthoxytétrahydro-2H-pyran-4-yl] aminé.
MA28957A 2003-10-27 2006-04-24 Sel antagonistes de ccr-2 MA28104A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51473503P 2003-10-27 2003-10-27

Publications (1)

Publication Number Publication Date
MA28104A1 true MA28104A1 (fr) 2006-08-01

Family

ID=34572774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28957A MA28104A1 (fr) 2003-10-27 2006-04-24 Sel antagonistes de ccr-2

Country Status (21)

Country Link
US (1) US7473696B2 (fr)
EP (1) EP1682135B1 (fr)
JP (1) JP4542550B2 (fr)
KR (1) KR20060101476A (fr)
CN (1) CN1870998B (fr)
AT (1) ATE517622T1 (fr)
AU (1) AU2004287416C1 (fr)
BR (1) BRPI0415836A (fr)
CA (1) CA2543201C (fr)
CO (1) CO5690606A2 (fr)
EC (1) ECSP066524A (fr)
IL (1) IL175009A0 (fr)
IS (1) IS8400A (fr)
MA (1) MA28104A1 (fr)
MX (1) MXPA06004647A (fr)
NO (1) NO20062377L (fr)
NZ (1) NZ546447A (fr)
RU (1) RU2317295C1 (fr)
UA (1) UA81365C2 (fr)
WO (1) WO2005044264A1 (fr)
ZA (1) ZA200602752B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
US7393844B2 (en) * 2003-03-18 2008-07-01 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl heterocyclic amide modulators of chemokine receptor activity
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
UA82917C2 (en) 2003-12-18 2008-05-26 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptor
KR100837019B1 (ko) 2004-05-11 2008-06-10 인사이트 코포레이션 케모카인 수용체 조절제로서3-(4-헤테로아릴사이클로헥실아미노)사이클로펜탄카복스아마이드
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
KR100856156B1 (ko) 2004-06-28 2008-09-03 인사이트 코포레이션 케모카인 수용체의 조절자로서의3-아미노사이클로펜탄카복스아마이드
AU2005259983B2 (en) 2004-06-28 2011-07-28 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CA2669917A1 (fr) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines utilises en tant qu'antagonistes du recepteur de la chimiokine
US20090076065A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk-0812
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012125663A2 (fr) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés d'amino cyclopentane substitués par cyclohexane en tant qu'antagonistes utiles de ccr2
WO2013149376A1 (fr) 2012-04-02 2013-10-10 Abbott Laboratories Antagonistes de récepteurs de chimiokines
EP2962691A4 (fr) 2013-02-28 2016-08-31 Santen Pharmaceutical Co Ltd Agent de prévention ou de traitement de maladies de la partie postérieure de l' il contenant un dérivé de tétrahydropyranylaminocyclopentylcarbonyltétrahydropyridopyridine en tant que principe actif
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
WO2019060820A1 (fr) 2017-09-25 2019-03-28 Chemocentryx, Inc. Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
WO2019136368A2 (fr) 2018-01-08 2019-07-11 Chemocentryx, Inc. Procédés de traitement de tumeurs solides au moyen d'antagonistes du ccr2
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112341350A (zh) * 2020-10-19 2021-02-09 江苏威奇达药业有限公司 酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
RU2174123C2 (ru) * 1996-10-28 2001-09-27 Новартис Аг Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2787790A1 (fr) * 1998-12-23 2000-06-30 Sanofi Sa Procede de preparation du (r)-(+)-3-{1[2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl]-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
AU5473400A (en) 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
JP2004506013A (ja) 2000-08-17 2004-02-26 メルク　エンド　カムパニー　インコーポレーテッド シクロペンチル系ケモカイン受容体活性調節剤
UA74221C2 (uk) * 2000-11-28 2005-11-15 Пфайзер Продактс Інк. Солі ізотіазол-4-карбоксаміду та їх використання як антигіперпроліферативних агентів
AU2002341327A1 (en) * 2001-11-29 2003-06-10 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
GEP20063872B (en) * 2001-12-12 2006-07-10 Pfizer Prod Inc Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2003093231A2 (fr) * 2002-04-29 2003-11-13 Merck & Co., Inc. Modulateurs de l'activite des recepteurs des chimiokines a base de tetrahydropyranyl cyclopentyl tetrahydroisoquinoline
DE60321333D1 (de) * 2002-04-29 2008-07-10 Merck Sharp & Dohme Tetrahydropyranyl-cyclopentyl-tetrahydropyridopyridin-modulatoren der chemokin-rezeptor-aktivität
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2

Also Published As

Publication number Publication date
CA2543201C (fr) 2010-12-21
US7473696B2 (en) 2009-01-06
EP1682135A1 (fr) 2006-07-26
MXPA06004647A (es) 2006-06-27
ZA200602752B (en) 2007-08-29
JP2007509940A (ja) 2007-04-19
EP1682135B1 (fr) 2011-07-27
IS8400A (is) 2006-04-06
WO2005044264A1 (fr) 2005-05-19
NZ546447A (en) 2009-02-28
ATE517622T1 (de) 2011-08-15
NO20062377L (no) 2006-05-24
AU2004287416C1 (en) 2010-09-09
ECSP066524A (es) 2006-10-10
CA2543201A1 (fr) 2005-05-19
UA81365C2 (en) 2007-12-25
CN1870998B (zh) 2010-10-20
RU2317295C1 (ru) 2008-02-20
CN1870998A (zh) 2006-11-29
IL175009A0 (en) 2006-08-20
AU2004287416B2 (en) 2009-11-19
KR20060101476A (ko) 2006-09-25
AU2004287416A1 (en) 2005-05-19
US20070135474A1 (en) 2007-06-14
BRPI0415836A (pt) 2007-01-02
EP1682135A4 (fr) 2009-11-25
JP4542550B2 (ja) 2010-09-15
CO5690606A2 (es) 2006-10-31

Similar Documents

Publication Publication Date Title
MA28104A1 (fr) Sel antagonistes de ccr-2
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
WO2006034039A3 (fr) Morphinanes substitues et leurs procedes d&#39;utilisation
IL166235A (en) H-1-pyrolidine-4,2-deion spirocyclic annihilated conjugates in cisal alkoxies for use as pesticides, their preparation and intermediates
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
DE60312701D1 (de) Darstellung von 1h-imidazoä4,5-cüchinolin-4-aminen über neue 1h-imidazoä4,5-cüchinolin-4-cyano- und 1h-imidazoä4,5-cüchinolin-4-carboxamid intermediate
WO2005037198A3 (fr) Preparation d&#39;azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases
WO2007013896A3 (fr) Composes modulant l&#39;activite de c-kit et c-fms et utilisations
WO2001066534A3 (fr) Antagonistes du recepteur d&#39;histamine-3 diamino cycliques et bicycliques
EP1675552A4 (fr) Preparation d&#39;azabenzimidazoles 1,6-disubstitues comme inhibiteurs de kinases
PL1622569T3 (pl) Pochodne aza spiro alkanów jako inhibitory metaloproteaz
GEP20074210B (en) Tropane derivatives as ccr5 modulators
RU2009140095A (ru) Гетероарильные производные
WO2002012224A3 (fr) Composes bicycliques
MXPA05008183A (es) Proceso para preparar pirrolotriazina como inhibidores de cinasa.
WO2005049561A3 (fr) Procedes de preparation d&#39;un nouveau derive de bleu de methylene
WO2004106340A3 (fr) Derives substitues en 4 de pyrazolo[3,4-d]pyrimidine et pyrrolo[2,3-d]pyrimidine et utilisations associees
WO2005044795A8 (fr) Procede d&#39;elaboration d&#39;antagoniste vis-a-vis du ccr-2
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
IS7492A (is) Lyfjablöndu uppskriftir, sem innifela melantónín
PL1730144T3 (pl) Podstawione pochodne 1,4,8-triazaspiro[4.5]dekan-2-onu
EP1786815A4 (fr) Composes spiro et procedes pour la modulation de l&#39;activite de recepteur de chimiokine
EA200501829A1 (ru) Способ получения непептидных замещённых спиробензоазепиновых производных
UA98797C2 (en) 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro -1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
HUP0103912A3 (en) Substituted alkylpyridazinone derivatives, process for their preparation, their use for the preparation of pharmaceutical compositions with anxiolytic activity